Search Within

Advanced Practice Providers

  1. "Maria Arcila"
Formats
  1. Meeting Abstract (21)
  2. Journal Article (7)
  3. Editorial (1)
Groups
  1. Department of Pathology and Laboratory Medicine (29)
  2. Department of Medicine (23)
  3. Epidemiology and Biostatistics (21)
  4. GSK Faculty (20)
  5. Human Oncology and Pathogenesis Program (20)
  6. Nursing (20)

More Groups

People
  1. Maria Arcila (29)
  2. Michael Berger (12)
  3. Ahmet Dogan (11)
  4. Marc Ladanyi (9)
  5. David Solit (7)
  6. Sergio Giralt (7)

More People

Years
  1. 2024 (4)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (2)
  5. 2020 (3)
  6. 2019 (7)

More Years

Publications
  1. Neuro-Oncology (6)
  2. Blood (5)
  3. Journal of Clinical Oncology (4)
  4. European Urology Focus (2)
  5. BJU International (1)
  6. Cancer Discovery (1)

More Publications

Publishers
  1. Oxford University Press (6)
  2. American Society of Hematology (5)
  3. American Society of Clinical Oncology (4)
  4. American Association for Cancer Research (2)
  5. Elsevier B.V. (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The integration of a liquid biopsy program into the care of pediatric brain tumor patients
    Meeting Abstract

    Miller, A.; Szalontay, L.; Ahmad, H.; Bouvier, N.; Rodriguez-Sanchez, I.; Bale, T.; Benayed, R.; Arcila, M.; Donzelli, M.; Dunkel, I.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Molecular stratification of high-grade unclassified renal cell carcinoma to improve prognostication and management strategy
    Meeting Abstract

    Chen, Y.; Di Natale, R. G.; Jayakumaran, G.; Ghanaat, M.; Marcon, J.; Brannon, A. R.; Al-Ahmadie, H.; Fine, S.; Gopalan, A.; Sirintrapun, S. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Characterization and impact of TERT promoter region mutations on clinical outcome in renal cell carcinoma
    Journal Article

    Casuscelli, J.; Becerra, M. F.; Manley, B. J.; Zabor, E. C.; Reznik, E.; Redzematovic, A.; Arcila, M. E.; Tennenbaum, D. M.; Ghanaat, M.; Kashan, M.; more...
    European Urology Focus (2019)

    Fulltext@MSK | Save
  • 89Zr-trastuzumab PET/CT for prediction of response to HER2-targeted therapy in patients with HER2 mutant lung cancer: An exploratory phase 2 trial
    Meeting Abstract

    Ulaner, G.; Offin, M.; Scaltriti, M.; Myers, M.; Venkatesh, A.; Panora, E.; Kris, M.; Rudin, C.; Arcila, M.; Lyashchenko, S.; more...
    Journal of Nuclear Medicine (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save